Scientists at acib and the University of Natural Resources Vienna develop world’s first continuous purification method for valuable drugs. This will lead to significantly reduced production costs and to cheaper pharmaceuticals that are affordable for non-privileged health care systems.
Imagine a dear relative suffering from cancer – and you could not afford a treatment because the drugs are too expensive. The Austrian Centre of Industrial Biotechnology (acib) developed a method with the power to reduce production costs of highly valued drugs significantly.
Without antibodies we would be at the mercy of pathogens or cancer cells. Therapeutic antibodies are used as passive vaccines, for cancer therapy or for controlling autoimmune diseases such as multiple sclerosis. According to “bccresearch.com” the global market for antibody drugs was worth nearly 70 billion USD in 2014 and should rise to 122 billion USD until 2019.
Two thirds of those molecules are produced biotechnologically using Chinese hamster ovary cells (CHO). Actually the major cost factor for industry is purification using “protein A” affinity chromatography where tens of thousands of liters of culture volume have to be processed annually. About 80 % of the production costs fall upon purification.
Here this new purification method comes into play. Researchers from the Austrian Centre of Industrial Biotechnology (acib) and the University of Natural Resources and Life Sciences Vienna (BOKU) developed the world’s first downstream processing method for recombinant antibodies from clarified CHO cultures. From a technical view, the purification method combines a Calcium-Phosphate flocculation with a subsequent cold ethanol precipitation in a tubular reactor realized as a double-pipe heat exchanger that is operated in counter-current flow.
A feasibility study exemplified by the purification of immune globulin G (IgG) shows that the continuous method can compete with “protein A” affinity chromatography in terms of yield and outperforms chromatography according to the speed of operation. A further advantage is that the operation parameters can be easily transferred from the actually used batch to the continuous approach. In combination with a prior concentration step the new method is perfect for purification of low titer supernatants. “Our method shows great potential as a new platform technology for the pharmaceutical industry”, says Prof. Alois Jungbauer, who is in negotiations with several international companies about building pilot plants.
The Latest on: Drug production
via Google News
The Latest on: Drug production
- Anti-Aging Drugs Market Know About Its Growth Driving Factors By Key Companies Like- Allergan, Johnson And Johnson, Nu Skinon January 22, 2020 at 11:57 pm
A complete outlook of Anti-Aging Drugs market revenue share, product development and innovation, advanced technologies, and new emerging market segments are studied. Global Anti-Aging Drugs Market ...
- Schizophrenia Drugs Market Strategic Recommendations, Business Plans 2018-2027on January 22, 2020 at 10:34 pm
Global Schizophrenia Drugs Market provides, wherever applicable and relevant, technical data of products, and sheds useful light on expected commercial production dates and current R&D status. This ...
- Health insurers take on Big Pharma, plan to manufacture their own drugson January 22, 2020 at 9:21 pm
A group of leading U.S. health insurers, frustrated by the high cost of prescription drugs, plan to start manufacturing versions of popular generic medications, hoping the competition with ...
- Sick of high drug prices, insurers join hospitals to make their own generic medicationson January 22, 2020 at 9:03 pm
Everyone complains about high drug prices. But hospitals — and now insurers — are trying to lower costs by manufacturing their own generic medications.
- Major Insurers Pledge $55 Million to Try to Lower Generic Drug Priceson January 22, 2020 at 9:01 pm
The Blue Cross Blue Shield Association and others say they have agreed to invest in a nonprofit’s effort to develop and sell cheaper drugs. A major group of insurers said it would invest $55 million ...
- Could this plan end price hikes, shortages of generic drugs?on January 22, 2020 at 7:52 pm
Californians and consumers around the world have been subjected to price gouging generic medications they need. Drug shortages and sharp price hikes prompted Gov. Newsom to propose the state get into ...
- Rheumatoid Arthritis Drugs Market Production Growth by Type forecast 2019 to 2025on January 22, 2020 at 8:28 am
The Rheumatoid Arthritis Drugs Market research report 2019 includes analysis of factual data that provides research results, vital recommendations, conclusions, and other important information to the ...
- Drug, nutrition product sales power Abbott's revenue beaton January 22, 2020 at 8:10 am
Medical device maker Abbott Laboratories Inc ( ABT.N) beat quarterly sales estimates on Wednesday, benefiting from higher demand for its nutrition products and generic drug sales. Shares of the ...
- A Common Practice of Widespread Antimicrobial Use in Horse Production Promotes Multi-Drug Resistanceon January 22, 2020 at 2:24 am
The GIT resistome was studied to determine if MaR or GaM treatment expanded the abundance or diversity of antimicrobioal resistance ARGs. Sequencing generated a total of 32,936,952 reads (median, ...
- Excedrin is temporarily stopping production of two drugs meant to treat migraineson January 21, 2020 at 9:14 am
It may soon be tough to find two types of Excedrin on shelves. Excedrin maker GlaxoSmithKline has halted production on caplets and gel tabs of Excedrin Extra Strength and Excedrin Migraine, a ...
via Bing News